Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.

Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P.

Biol Blood Marrow Transplant. 2018 Dec 21. pii: S1083-8791(18)30963-7. doi: 10.1016/j.bbmt.2018.12.141. [Epub ahead of print]

PMID:
30579965
2.

Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018.

Kabir TF, Chauhan A, Anthony L, Hildebrandt GC.

Ochsner J. 2018 Winter;18(4):370-376. doi: 10.31486/toj.18.0055. Review.

3.

Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.

Kumari R, Palaniyandi S, Hildebrandt GC.

Dig Dis Sci. 2018 Dec 7. doi: 10.1007/s10620-018-5369-9. [Epub ahead of print] Review.

PMID:
30523482
4.

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovó A, Schears R, Shah A, Agrawal V, Ahmed A, Ahmed I, Ali A, Aljurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Callander N, Fahnehjelm K, Farhadfar N, Gale RP, Ganguly S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penack O, Pingali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Wirk B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Valdés-Sanz N.

Bone Marrow Transplant. 2018 Dec 7. doi: 10.1038/s41409-018-0339-6. [Epub ahead of print] Review.

PMID:
30531955
5.

Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.

Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovó A, Schears R, Shah A, Agrawal V, Ahmed A, Ahmed I, Ali A, Aljurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Callander N, Fahnehjelm K, Farhadfar N, Gale RP, Ganguly S, Hashmi S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penack O, Pingali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Wirk B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Valdés-Sanz N.

Biol Blood Marrow Transplant. 2018 Dec 3. pii: S1083-8791(18)30798-5. doi: 10.1016/j.bbmt.2018.11.033. [Epub ahead of print] Review.

PMID:
30521975
6.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W.

Blood Adv. 2018 Nov 13;2(21):2922-2936. doi: 10.1182/bloodadvances.2018024844.

7.

Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.

Norkin M, Shaw BE, Brazauskas R, Tecca HR, Leather HL, Gea-Banacloche J, T Kamble R, DeFilipp Z, Jacobsohn DA, Ringden O, Inamoto Y, A Kasow K, Buchbinder D, Shaw P, Hematti P, Schears R, Badawy SM, Lazarus HM, Bhatt N, Horn B, Chhabra S, M Page K, Hamilton B, Hildebrandt GC, Yared JA, Agrawal V, M Beitinjaneh A, Majhail N, Kindwall-Keller T, Olsson RF, Schoemans H, Gale RP, Ganguly S, A Ahmed I, Schouten HC, L Liesveld J, Khera N, Steinberg A, Shah AJ, Solh M, Marks DI, Rybka W, Aljurf M, Dietz AC, Gergis U, George B, Seo S, Flowers MED, Battiwalla M, Savani BN, Riches ML, Wingard JR.

Biol Blood Marrow Transplant. 2019 Feb;25(2):362-368. doi: 10.1016/j.bbmt.2018.09.031. Epub 2018 Oct 2.

PMID:
30287390
8.

Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.

Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2443-2449. doi: 10.1016/j.bbmt.2018.08.013. Epub 2018 Aug 22.

PMID:
30142419
9.

Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.

Alhakeem SS, McKenna MK, Oben KZ, Noothi SK, Rivas JR, Hildebrandt GC, Fleischman RA, Rangnekar VM, Muthusamy N, Bondada S.

J Immunol. 2018 Jun 15;200(12):4180-4189. doi: 10.4049/jimmunol.1800241. Epub 2018 Apr 30.

PMID:
29712773
10.

Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.

McKenna MK, Noothi SK, Alhakeem SS, Oben KZ, Greene JT, Mani R, Perry KL, Collard JP, Rivas JR, Hildebrandt GC, Fleischman RA, Durbin EB, Byrd JC, Wang C, Muthusamy N, Rangnekar VM, Bondada S.

Blood. 2018 Jun 28;131(26):2943-2954. doi: 10.1182/blood-2017-10-813931. Epub 2018 Apr 25.

PMID:
29695515
11.

Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma.

Hildebrandt GC, Berno T, Gurule A, Mohan M, Yoon D, Salama M, Zangari M.

Br J Haematol. 2019 Jan;184(2):308-310. doi: 10.1111/bjh.15095. Epub 2018 Mar 24. No abstract available.

PMID:
29574687
12.

Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort.

Saeed H, Yalamanchi S, Liu M, Van Meter E, Gul Z, Monohan G, Howard D, Hildebrandt GC, Herzig R.

Hematol Oncol Stem Cell Ther. 2018 Jun;11(2):90-95. doi: 10.1016/j.hemonc.2017.12.002. Epub 2018 Feb 3.

13.

Pulmonary Injury and Chronic Graft-versus-Host Disease: Do We Miss the Signs and Symptoms?

Hildebrandt GC.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1605-1606. doi: 10.1016/j.bbmt.2017.08.015. Epub 2017 Aug 16. No abstract available.

14.

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.

Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A.

Blood. 2017 Aug 31;130(9):1156-1164. doi: 10.1182/blood-2017-03-772368. Epub 2017 Jul 3.

15.

Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease.

Ramlal R, Hildebrandt GC.

Biomedicines. 2017 May 16;5(2). pii: E23. doi: 10.3390/biomedicines5020023. Review.

16.

Pulmonary arterial hypertension in primary amyloidosis.

Cirulis MM, Emerson LL, Bull DA, Hatton N, Nativi-Nicolai J, Hildebrandt GC, Ryan JJ.

Pulm Circ. 2016 Jun;6(2):244-8. doi: 10.1086/686172.

17.
18.

Bronchiolitis Obliterans: Pleading for a Pragmatic Approach.

Wolff D, Hildebrandt GC.

Biol Blood Marrow Transplant. 2016 Apr;22(4):591-593. doi: 10.1016/j.bbmt.2016.01.022. Epub 2016 Jan 21. No abstract available.

19.
20.
21.

A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population.

Radhakrishnan SV, Hildebrandt GC.

Curr Hematol Malig Rep. 2015 Mar;10(1):8-17. doi: 10.1007/s11899-014-0244-z.

PMID:
25662904
22.

Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.

Radhakrishnan SV, Palaniyandi S, Mueller G, Miklos S, Hager M, Spacenko E, Karlsson FJ, Huber E, Kittan NA, Hildebrandt GC.

Biol Blood Marrow Transplant. 2015 Jan;21(1):30-8. doi: 10.1016/j.bbmt.2014.09.025. Epub 2014 Oct 17.

23.

Double hit lymphoma - a case of unusual response after sequential aggressive chemotherapy and review of the literature.

Cheema FN, Agloria M, Koshy N, Hildebrandt GC.

Clin Med Insights Case Rep. 2014 Oct 1;7:117-21. doi: 10.4137/CCRep.S11393. eCollection 2014.

24.

Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage.

Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Graeff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schönle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Häcker H, Hildebrandt GC, Häcker G, Zeiser R.

Nat Med. 2014 Jun;20(6):648-54. doi: 10.1038/nm.3517. Epub 2014 May 18.

PMID:
24836575
25.

Regression of eosinophil counts after diagnosis of chronic graft-versus-host disease as a potential marker for improved clinical outcome.

Beier F, Arbter K, Kittan NA, Andreesen R, Krause SW, Holler E, Hildebrandt GC.

Mol Clin Oncol. 2014 Jan;2(1):81-86. Epub 2013 Sep 25.

26.

Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection.

Palaniyandi S, Radhakrishnan SV, Karlsson FJ, Stokes KY, Kittan N, Huber E, Hildebrandt GC.

PLoS One. 2013 Apr 15;8(4):e61841. doi: 10.1371/journal.pone.0061841. Print 2013.

27.

Graft-versus-lymphoma effect plus vorinostat as successful approach in a case of refractory gastric peripheral T cell lymphoma, not otherwise specified, after reduced intensity conditioning allogeneic hematopoietic cell transplant.

Devarakonda SS, Shahan JL, Takalkar A, Chaudhery SI, Jean G, Koshy NV, Hildebrandt GC.

Leuk Lymphoma. 2013 Nov;54(11):2545-7. doi: 10.3109/10428194.2013.776682. Epub 2013 Aug 13. No abstract available.

PMID:
23442066
28.

Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers.

Wolff D, Ayuk F, Elmaagacli A, Bertz H, Lawitschka A, Schleuning M, Meyer RG, Gerbitz A, Hilgendorf I, Hildebrandt GC, Edinger M, Klein S, Halter J, Mousset S, Holler E, Greinix HT.

Biol Blood Marrow Transplant. 2013 May;19(5):767-76. doi: 10.1016/j.bbmt.2013.01.018. Epub 2013 Jan 29.

29.

Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.

Shahan JL, Panu LD, Hildebrandt GC.

Int J Hematol. 2012 Dec;96(6):818-9. doi: 10.1007/s12185-012-1226-3. Epub 2012 Nov 28. No abstract available.

PMID:
23188472
30.

Development of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma 13 years after treatment with cladribine.

Berghoff M, Schänzer A, Hildebrandt GC, Dassinger B, Klappstein G, Kaps M, Gizewski ER, Acker T, Grams A.

Leuk Lymphoma. 2013 Jun;54(6):1340-2. doi: 10.3109/10428194.2012.740669. Epub 2012 Nov 20. No abstract available.

PMID:
23098217
31.

Successful treatment of first and second recurrence of acute lymphoblastic leukemia after related allogeneic bone marrow transplant at unusual sites using single-dose vincristine followed by interferon-α2b and granulocyte-macrophage colony-stimulating factor.

Volodin L, Peddi P, Takalkar A, Comeau JM, Shahan JL, Hildebrandt GC.

Leuk Lymphoma. 2013 May;54(5):1107-9. doi: 10.3109/10428194.2012.734617. Epub 2012 Oct 16. No abstract available.

PMID:
23020692
32.

Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.

Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, Pavletic SZ, Holler E, Wolff D.

Bone Marrow Transplant. 2011 Oct;46(10):1283-95. doi: 10.1038/bmt.2011.35. Epub 2011 Mar 28. Review.

PMID:
21441964
33.

Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges.

Kittan NA, Beier F, Kurz K, Niller HH, Egger L, Jilg W, Andreesen R, Holler E, Hildebrandt GC.

Transpl Infect Dis. 2011 Oct;13(5):524-30. doi: 10.1111/j.1399-3062.2011.00621.x. Epub 2011 Mar 13.

PMID:
21395956
34.

Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract.

Bouazzaoui A, Spacenko E, Mueller G, Huber E, Schubert T, Holler E, Andreesen R, Hildebrandt GC.

Exp Hematol. 2011 Feb;39(2):238-249.e1. doi: 10.1016/j.exphem.2010.11.006. Epub 2010 Nov 22.

PMID:
21108989
35.

Identification of CD133(-)/telomerase(low) progenitor cells in glioblastoma-derived cancer stem cell lines.

Beier F, Beier CP, Aschenbrenner I, Hildebrandt GC, Brümmendorf TH, Beier D.

Cell Mol Neurobiol. 2011 Apr;31(3):337-43. doi: 10.1007/s10571-010-9627-4. Epub 2010 Nov 17.

PMID:
21082235
36.

Successful treatment of Scedosporium apiospermum soft tissue abscess with caspofungin and voriconazole in a severely immunocompromised patient with acute myeloid leukemia.

Beier F, Kittan N, Holzmann T, Schardt K, Andreesen R, Holler E, Hildebrandt GC.

Transpl Infect Dis. 2010 Dec;12(6):538-42. doi: 10.1111/j.1399-3062.2010.00537.x.

PMID:
20604906
37.

Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.

Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, Elad S, Lawitschka A, Socie G, Pavletic SZ, Holler E, Greinix H.

Biol Blood Marrow Transplant. 2010 Dec;16(12):1611-28. doi: 10.1016/j.bbmt.2010.06.015. Epub 2010 Jun 25.

38.

The chemokine system: a possible therapeutic target in acute graft versus host disease.

Kittan NA, Hildebrandt GC.

Curr Top Microbiol Immunol. 2010;341:97-120. doi: 10.1007/82_2010_23. Review.

PMID:
20379809
39.

G to C transition at position -173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation.

Chang YY, Greinix HT, Dickinson AM, Wolff D, Jackson GH, Andreesen R, Holler E, Hildebrandt GC.

Cytokine. 2009 Dec;48(3):218-25. doi: 10.1016/j.cyto.2009.07.012. Epub 2009 Aug 31.

PMID:
19720544
40.

Principles of modular tumor therapy.

Reichle A, Hildebrandt GC.

Cancer Microenviron. 2009 Sep;2 Suppl 1:227-37. doi: 10.1007/s12307-009-0023-x. Epub 2009 Jul 11.

41.

Chemokine and chemokine receptor expression analysis in target organs of acute graft-versus-host disease.

Bouazzaoui A, Spacenko E, Mueller G, Miklos S, Huber E, Holler E, Andreesen R, Hildebrandt GC.

Genes Immun. 2009 Dec;10(8):687-701. doi: 10.1038/gene.2009.49. Epub 2009 Jul 2.

PMID:
19571824
42.

Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease.

Miklos S, Mueller G, Chang Y, Bouazzaoui A, Spacenko E, Schubert TEO, Grainger DJ, Holler E, Andreesen R, Hildebrandt GC.

Int J Hematol. 2009 Apr;89(3):383-397. doi: 10.1007/s12185-009-0272-y. Epub 2009 Mar 14.

PMID:
19288173
43.

Pulmonary function changes in experimental graft-versus-host disease of the lung.

Miklos S, Mueller G, Chang Y, Schubert TEO, Holler E, Hildebrandt GC.

Biol Blood Marrow Transplant. 2008 Sep;14(9):1004-1016. doi: 10.1016/j.bbmt.2008.06.015.

44.

A role for TNF receptor type II in leukocyte infiltration into the lung during experimental idiopathic pneumonia syndrome.

Hildebrandt GC, Olkiewicz KM, Corrion L, Clouthier SG, Pierce EM, Liu C, Cooke KR.

Biol Blood Marrow Transplant. 2008 Apr;14(4):385-96. doi: 10.1016/j.bbmt.2008.01.004.

45.

Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation.

Hildebrandt GC, Granell M, Urbano-Ispizua A, Wolff D, Hertenstein B, Greinix HT, Brenmoehl J, Schulz C, Dickinson AM, Hahn J, Rogler G, Andreesen R, Holler E.

Biol Blood Marrow Transplant. 2008 Jan;14(1):67-74.

46.
47.

CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation.

Choi SW, Hildebrandt GC, Olkiewicz KM, Hanauer DA, Chaudhary MN, Silva IA, Rogers CE, Deurloo DT, Fisher JM, Liu C, Adams D, Chensue SW, Cooke KR.

Blood. 2007 Nov 1;110(9):3447-55. Epub 2007 Jul 19.

48.

The absence of donor-derived IL-13 exacerbates the severity of acute graft-versus-host disease following allogeneic bone marrow transplantation.

Hildebrandt GC, Choi SW, Mueller G, Olkiewicz KM, Moore BB, Cooke KR.

Pediatr Blood Cancer. 2008 Apr;50(4):911-4.

49.

Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease.

Ewing P, Miklos S, Olkiewicz KM, Müller G, Andreesen R, Holler E, Cooke KR, Hildebrandt GC.

Exp Hematol. 2007 Jan;35(1):155-63.

PMID:
17198884
50.

Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation.

Hildebrandt GC, Olkiewicz KM, Choi S, Corrion LA, Clouthier SG, Liu C, Serody JS, Cooke KR.

Blood. 2005 Mar 15;105(6):2249-57. Epub 2004 Nov 16.

Supplemental Content

Loading ...
Support Center